Revelation Biosciences (REVB) Free Cash Flow (2020 - 2025)
Revelation Biosciences (REVB) posted quarterly Free Cash Flow of -$2.0 million for Q4 2025, up 47.26% year-over-year from -$1.3 million in Q4 2024, and down 23.8% quarter-over-quarter from -$1.6 million in Q3 2025.
Revelation Biosciences (REVB) Free Cash Flow (2020 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Free Cash Flow for 6 consecutive years, with -$2.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 47.26% year-over-year to -$2.0 million; the TTM figure through Dec 2025 stood at -$8.3 million (up 54.91% YoY), while the FY2025 annual figure was -$8.3 million, up 54.91% from the prior year.
- Free Cash Flow slipped to -$2.0 million in Q4 2025 per REVB's latest filing, from -$1.6 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$947467.0 in Q4 2022 and bottomed at -$9.3 million in Q3 2024.
- Historically, Free Cash Flow has averaged -$2.8 million across 5 years, with a median of -$2.4 million in 2021.
- Annual changes were most pronounced in 2021 — Free Cash Flow sank 257349.31% — and 2025, when it soared 82.87%.
- Revelation Biosciences' Free Cash Flow stood at -$2.9 million in 2021, then soared by 66.9% to -$947467.0 in 2022, then plunged by 111.39% to -$2.0 million in 2023, then sank by 86.23% to -$3.7 million in 2024, then soared by 47.26% to -$2.0 million in 2025.
- Business Quant data shows REVB's Free Cash Flow at -$2.0 million in Q4 2025, -$1.6 million in Q3 2025, and -$1.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.97 Mn |
| Dec 31, 2025 | -1.97 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Sep 30, 2025 | -1.59 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Jun 30, 2025 | -1.92 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Mar 31, 2025 | -2.79 Mn |
| Dec 31, 2024 | -3.73 Mn |
| Dec 31, 2024 | -3.73 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Sep 30, 2024 | -9.27 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Jun 30, 2024 | -2.48 Mn |
| Mar 31, 2024 | -2.86 Mn |
| Mar 31, 2024 | -2.86 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Dec 31, 2023 | -2.00 Mn |
| Sep 30, 2023 | -1.72 Mn |
| Sep 30, 2023 | -1.72 Mn |